Article thumbnail

GLI1 Confers Profound Phenotypic Changes upon LNCaP Prostate Cancer Cells That Include the Acquisition of a Hormone Independent State

By Sandeep K. Nadendla, Allon Hazan, Matt Ward, Lisa J. Harper, Karwan Moutasim, Lucia S. Bianchi, Mahmoud Naase, Lucy Ghali, Gareth J. Thomas, David M. Prowse, Michael P. Philpott and Graham W. Neill

Abstract

The GLI (GLI1/GLI2) transcription factors have been implicated in the development and progression of prostate cancer although our understanding of how they actually contribute to the biology of these common tumours is limited. We observed that GLI reporter activity was higher in normal (PNT-2) and tumourigenic (DU145 and PC-3) androgen-independent cells compared to androgen-dependent LNCaP prostate cancer cells and, accordingly, GLI mRNA levels were also elevated. Ectopic expression of GLI1 or the constitutively active ΔNGLI2 mutant induced a distinct cobblestone-like morphology in LNCaP cells that, regarding the former, correlated with increased GLI2 as well as expression of the basal/stem-like markers CD44, β1-integrin, ΔNp63 and BMI1, and decreased expression of the luminal marker AR (androgen receptor). LNCaP-GLI1 cells were viable in the presence of the AR inhibitor bicalutamide and gene expression profiling revealed that the transcriptome of LNCaP-GLI1 cells was significantly closer to DU145 and PC-3 cells than to control LNCaP-pBP (empty vector) cells, as well as identifying LCN2/NGAL as a highly induced transcript which is associated with hormone independence in breast and prostate cancer. Functionally, LNCaP-GLI1 cells displayed greater clonal growth and were more invasive than control cells but they did not form colonies in soft agar or prostaspheres in suspension suggesting that they do not possess inherent stem cell properties. Moreover, targeted suppression of GLI1 or GLI2 with siRNA did not reverse the transformed phenotype of LNCaP-GLI1 cells nor did double GLI1/GLI2 knockdowns activate AR expression in DU145 or PC-3 cells. As such, early targeting of the GLI oncoproteins may hinder progression to a hormone independent state but a more detailed understanding of the mechanisms that maintain this phenotype is required to determine if their inhibition will enhance the efficacy of anti-hormonal therapy through the induction of a luminal phenotype and increased dependency upon AR function

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3102098
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers.
  2. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer.
  3. (2006). A potential role of alternative splicing in the regulation of the transcriptional activity of human GLI2 in gonadal tissues.
  4. (2005). A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2.
  5. (2009). ABC transporters, drug resistance, and cancer stem cells.
  6. (1999). Analysis and sorting of prostate cancer cell types by flow cytometry.
  7. (2009). Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells.
  8. (2010). Basal epithelial stem cells are efficient targets for prostate cancer initiation.
  9. (2010). betacatenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.
  10. (2005). Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
  11. (2008). Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
  12. (2007). Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?
  13. (2008). CD44+ CD24(2) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
  14. (2010). Claudin 1 in breast tumorigenesis: revelation of a possible novel ‘‘claudin high’’ subset of breast cancers.
  15. (2007). Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.
  16. (1998). Cloning of novel isoforms of the human Gli2 oncogene and their activities to enhance tax-dependent transcription of the human T-cell leukemia virus type 1 genome.
  17. (1992). Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.
  18. (2008). Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
  19. (2010). Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals.
  20. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery.
  21. (2009). Development of mammary tumors by conditional expression of GLI1.
  22. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.
  23. (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
  24. (2001). Expression of basal cell keratins in human prostate cancer metastases and cell lines.
  25. (2009). Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth. Breast Cancer Res Treat.
  26. (2009). Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.
  27. (2006). Fused kinase is stabilized by Cdc37/Hsp90 and enhances Gli protein levels.
  28. (2006). GLI transcription factors: mediators of oncogenic Hedgehog signalling.
  29. (2008). GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes.
  30. (2011). GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor.
  31. (2006). Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase.
  32. (2008). GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
  33. (2009). Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours.
  34. (2010). Hedgehog beyond medulloblastoma and basal cell carcinoma.
  35. (2007). Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis.
  36. (2009). Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
  37. (2007). Hedgehog signaling in the prostate.
  38. (2004). Hedgehog signaling promotes prostate xenograft tumor growth.
  39. (2008). Hedgehog signalling in androgen independent prostate cancer.
  40. (2004). Hedgehog signalling in prostate regeneration, neoplasia and metastasis.
  41. (2010). Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
  42. (1998). Heterogeneous expression of the lipocalin NGAL in primary breast cancers.
  43. (2007). Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.
  44. HuangdaW,ShermanBT,LempickiRA(2009)Systematicandintegrativeanalysis of large gene lists using DAVID bioinformatics resources.
  45. (2002). Human prostate epithelial cell-type cDNA libraries and prostate expression patterns.
  46. (2010). Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.
  47. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
  48. (2000). In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates.
  49. (2009). In vitro propagation and characterization of neoplastic stem/progenitorlike cells from human prostate cancer tissue.
  50. (1998). Increased incidence of matrix metalloproteinases in urine of cancer patients.
  51. (2007). Induction of sonic hedgehog mediators by transforming growth factor-beta:
  52. (2007). Inhibition of GLImediated transcription and tumor cell growth by small-molecule antagonists.
  53. (2004). Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.
  54. (2009). Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis.
  55. (2009). Lipocalin 2 promotes breast cancer progression.
  56. (2007). Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.
  57. (2003). Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma.
  58. (2008). Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma.
  59. (2000). Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.
  60. (1998). Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
  61. (2010). Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
  62. (2010). miR 488* inhibits androgen receptor expression in prostate carcinoma cells.
  63. (2008). Novel human glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal.
  64. (2006). Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling.
  65. (2001). Post-transcriptional regulation of the gli1 oncogene by the expression of alternative 59 untranslated regions.
  66. (2005). Prospective identification of tumorigenic prostate cancer stem cells.
  67. (2009). protein expression in ER negative breast cancer correlates with markers of the basal phenotype.
  68. (2006). Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling.
  69. (2005). proteins and mRNA expression in benign and malignant breast lesions: a research study.
  70. (2006). Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.
  71. (2011). Revisiting the concept of cancer stem cells in prostate cancer.
  72. (2007). Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells.
  73. (2006). Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.
  74. (2007). Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
  75. (2007). Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport.
  76. (2006). Sonic Hedgehog signaling in advanced prostate cancer.
  77. (2010). Steroid receptor and microRNA regulation in cancer.
  78. (2001). The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/ MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.
  79. (1998). The PTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
  80. (2008). The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.
  81. (2009). The role of microRNA221 and microRNA-222 in androgen-independent prostate cancer cell lines.
  82. (2006). TM4 microarray software suite.
  83. (2003). TM4: a free, opensource system for microarray data management and analysis.
  84. (2008). Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells.
  85. (2010). Transgelin Promotes Migration and Invasion of Cancer Stem Cells. J Proteome Res.
  86. (2008). Widespread deregulation of microRNA expression in human prostate cancer.